



c-Src Positive Control  
Product Data Sheet

For Research Use Only, Not for use in diagnostic procedures

## c-Src Positive Control

(Human, recombinant protein expressed in Sf9)  
Cat# CY-E1083

Lot No.  
For 100 Assays  
(1 unit /  $\mu\text{L}$  x 100  $\mu\text{L}$ )

### Product Description:

Catalytic domain of human Src, corresponding to 226-536 a.a. containing a N-terminal GST tag and a C-terminal His tag, expressed in recombinant Baculovirus-infected sf9 cells. Purified by sequentially using GSH agarose and Ni-NTA agarose chromatography. The Src Positive control is designed to use for CycLex Src Kinase Assay/Inhibitor Screening Kit (Cat# CY-1083). The Src Positive Control should be added to the well at 1 unit/well. For instance, diluted positive control 1:10, use 10  $\mu\text{L}$  for 1 assay. Unused Src Positive Control should be stored at  $-70^{\circ}\text{C}$ .

**Product Size:** Recombinant Src: 100 units/100  $\mu\text{L}$

**Formulation:** The Src Positive Control is supplied frozen in a buffer containing 20mM Hepes-KOH (pH 7.5), 1 % BSA, 1mM EDTA, 2 mM DTT, 50mM NaCl, 0.03 % Brij35 and 50% glycerol.

**Source:** Human Src containing N-terminal GST-tag and C-terminal His tag, expressed in sf9 cells.

**Molecular Weight:** Src Positive Control demonstrates a single 60 kDa bands by SDS-PAGE analysis.

**Purity:** Src Positive Control is greater than 70 % pure as determined by SDS-PAGE analysis.

**Substrates:** Src phosphorylates poly[Glu, Tyr] 4:1 as an exogenous substrate.

**Inhibitors:** PP2 is known as selective small molecule Src inhibitor.

**Unit Definition:** One unit is defined as the amount of kinase required to incorporate 1 nmol of phosphate into the Src (autophosphorylation) under oligomerized and activated condition per 60 minute at  $30^{\circ}\text{C}$ .

**Assay Conditions:** Assay activity of Src in a 50  $\mu\text{L}$  reaction containing 20 mM Hepes KOH (pH 7.5), 4 mM  $\text{MgCl}_2$ , 2 mM  $\text{MnCl}_2$ , 1 mM DTT, 50  $\mu\text{M}$  [ $\gamma$ - $^{32}\text{P}$ ] ATP (1  $\mu\text{Ci}$ ), and 4  $\mu\text{g}$  of CycLex-"Tyrosine kinase-binding module". Start the reaction by adding 10 $\mu\text{L}$  of the enzyme, diluted 10-fold in a buffer containing 20 mM Hepes KOH (pH 7.5), 1 mM DTT, 0.03 % Brij35. Incubate for 60 minutes at  $30^{\circ}\text{C}$ . Terminate the reaction by adding 600  $\mu\text{L}$  of cold 10 % TCA solution containing 0.2 % Sodium pyrophosphate and stand on ice for 15 min. Filtrate acid insoluble material through GFC filters (Whatman Inc.), wash 4 times with 1 % TCA and rinse filters with ethanol. Dry filters and count in a liquid scintillation counter.

**Storage and Stability:** Stable for 12 months at  $-70^{\circ}\text{C}$  from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot enzyme to avoid repeated freezing and thawing.



c-Src Positive Control  
Product Data Sheet

**For Research Use Only, Not for use in diagnostic procedures**

**Related Products:**

\* CycLex c-Src Kinase Assay/Inhibitor Screening Kit: Cat# CY-1083

**References:**

1. Parsons, J. T., and Parsons, S. J. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. *Curr. Opin. Cell Biol.*, **9**: 187–192, 1997
2. Erpel, T., and Courtneidge, S. A. Src family protein tyrosine kinases and cellular signal transduction pathways. *Curr. Opin. Cell Biol.*, **7**: 176–182, 1995
3. Brickell, P. M. The p60c-src family of protein-tyrosine kinases: structure, regulation, and function. *Crit. Rev. Oncog.*, **3**: 401–446, 1992
4. Collett, M. S., Brugge, J. S., and Erikson, R. L. Characterization of a normal avian cell protein related to the avian sarcoma virus transforming gene product. *Cell*, **15**:1363–1369, 1978
5. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. *Cancer Metastasis Rev.* **22**(4):337-58, 2003
6. Guy, C. T., Muthuswamy, S. K., Cardiff, R. D., Soriano, P., and Muller, W. J. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. *Genes Dev.*, **8**: 23–32, 1994
7. Irby, R. B.; Mao, W.; Coppola, D.; Kang, J.; Loubeau, J. M.; Trudeau, W.; Karl, R.; Fujita, D. J.; Jove, R.; Yeatman, T. J. : Activating SRC mutation in a subset of advanced human colon cancers. *Nature Genet.* **21**: 187-190, 1999

**PRODUCED BY**

CycLex Co., Ltd.  
1063-103 Terasawaoka  
Ina, Nagano 396-0002  
Japan  
Fax: +81-265-76-7618  
e-mail: [info@cyclex.co.jp](mailto:info@cyclex.co.jp)  
URL: <http://www.cyclex.co.jp>

**CycLex/CircuLex products are supplied for research use only. CycLex/CircuLex products and components thereof may not be resold, modified for resale, or used to manufacture commercial products without prior written approval from CycLex Co., Ltd.. To inquire about licensing for such commercial use, please contact us via email.**